SCHEMBL3624015

SCHEMBL3624015

Cc1cn(S(=O)(=O)c2ccccc2)c2cccc(CN(C)C)c12

nearest known ligand 0.64

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 18/20 0.64
DRD2 P14416 3/20 0.52
HTR1A P08908 2/20 0.52
HTR1D P28221 2/20 0.52
HTR1B P28222 2/20 0.52
HTR1F P30939 2/20 0.52
HTR7 P34969 2/20 0.52
DRD3 P35462 2/20 0.52
HTR2A P28223 1/20 0.46
HDAC1 Q13547 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC6 Q9UBN7 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3617242 0.91 HTR6 (0.55) HTR6DRD2HTR1AHTR1DHTR1B
SCHEMBL3619795 0.79 HTR6 (0.64) HTR6
SCHEMBL1171841 0.79 HTR6 (1.00) HTR6DRD2HTR1AHTR1DHTR1B
SCHEMBL3617243 0.77 HTR6 (0.78) HTR6
SCHEMBL3619076 0.77 HTR6 (0.52) HTR6
SCHEMBL3622989 0.76 HTR6 (0.67) HTR6
SCHEMBL3622409 0.76 HTR6 (0.77) HTR6DRD2HTR1AHTR1DHTR1B
SCHEMBL18585098 0.75 L3MBTL1 (0.52) HTR6HTR1DHTR1BDRD3
SCHEMBL3623180 0.75 KDM4E (0.56) HTR6HTR2AHDAC1HDAC2HDAC6
SCHEMBL3623692 0.74 HTR6 (0.46) HTR6HTR2AHDAC1HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2046741-B1 INDOLES AS 5-HT6 MODULATORS PROXIMAGEN LTD (GB) 2012-10-31 EP claimed
US-7812017-B2 4-substituted indole and indoline compounds BIOVITRUM AB (PUBL.) (SE) 2010-10-12 US claimed
US-20080032968-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2008-02-07 US claimed
EP-2046741-B1 INDOLES AS 5-HT6 MODULATORS PROXIMAGEN LTD (GB) 2012-10-31 EP disclosed
US-7812017-B2 4-substituted indole and indoline compounds BIOVITRUM AB (PUBL.) (SE) 2010-10-12 US disclosed
US-7812017-B2 4-substituted indole and indoline compounds BIOVITRUM AB (PUBL.) (SE) 2010-10-12 US disclosed
US-7812017-B2 4-substituted indole and indoline compounds BIOVITRUM AB (PUBL.) (SE) 2010-10-12 US disclosed
US-20080032968-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2008-02-07 US disclosed
US-20080032968-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2008-02-07 US disclosed
US-20080032968-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2008-02-07 US disclosed
WO-2008003703-A1 INDOLES AS 5-HT6 MODULATORS BIOVITRUM AB (PUBL) (SE) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032968-A1 New compounds HTR6, HTR1B, HTR1A HTR6 1/4885DRD2 41/4885HTR1A 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.